Eli Lilly’s quarter was messy. What to do with the stock is more clear-cut

Earnings

Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.
Cristina Arias | Cover | Getty Images

Eli Lilly shares fell Wednesday after the diabetes-and-obesity drug giant posted disappointing third-quarter results and lowered its full-year sales guidance. The report was messy, but it doesn’t dim Eli Lilly’s bright multiyear outlook, rendering the dip in the stock as a chance to buy.

Articles You May Like

The next big career track at business schools: Family offices
Top Wall Street analysts are upbeat on these dividend stocks
Solar stocks tumble overnight as Trump leads in election results
New Starbucks CEO shares more details on his turnaround plan. We like what we heard
Inflation is down — but the middle class is still feeling financial pressure. Here’s why

Leave a Reply

Your email address will not be published. Required fields are marked *